1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Pipeline Review, H1 2020, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.
Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively.
Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Prosthetic Joint infections - Overview
- Prosthetic Joint infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Prosthetic Joint infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Prosthetic Joint infections - Companies Involved in Therapeutics Development
- Armata Pharmaceuticals Inc
- Arrevus Inc
- ContraFect Corp
- Lumobiotics GmbH
- Peptilogics Inc
- Sonoran Biosciences Inc
- Telephus Medical LLC
- TenNor Therapeutics Ltd
- Prosthetic Joint infections - Drug Profiles
- Product Description
- Mechanism Of Action
- R&D Progress
- APSA-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- APSA-02 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CF-296 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- exebacase - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fusidic acid - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- PLG-0206 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules for Oncology and Infectious Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TNP-2092 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TPH-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Prosthetic Joint infections - Dormant Projects
- Prosthetic Joint infections - Discontinued Products
- Prosthetic Joint infections - Product Development Milestones
- Featured News & Press Releases
- Feb 25, 2020: Peptilogics announces CARB-X funding to accelerate development of first-in-class antibiotics to address the global threat of multi-drug resistant bacteria
- Jan 20, 2020: TenNor Therapeutics received FDA orphan drug designation
- Jan 13, 2020: ContraFect partners with leading orthopedic center in Europe to provide compassionate use of exebacase to patients with chronic staphylococcal prosthetic joint infections
- Oct 15, 2018: Peptilogics receives regulatory approval to initiate first-in-human safety study for therapeutic peptide PLG0206
- Aug 24, 2018: Peptilogics completes successful pre-IND meeting with the Food and Drug Administration for PLG0206 in Prosthetic Joint Infections
- Jun 02, 2018: Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
- Oct 29, 2013: Cempra Receives U.S. Orphan Drug Designation for Taksta for Treatment of Prosthetic Joint Infections
- Dec 14, 2012: Cempra Announces Initiation Of CEM-102 Phase II Clinical Trial In Patients With Prosthetic Joint Infections
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Prosthetic Joint infections, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
- Prosthetic Joint infections - Pipeline by Arrevus Inc, H1 2020
- Prosthetic Joint infections - Pipeline by ContraFect Corp, H1 2020
- Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, H1 2020
- Prosthetic Joint infections - Pipeline by Peptilogics Inc, H1 2020
- Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, H1 2020
- Prosthetic Joint infections - Pipeline by Telephus Medical LLC, H1 2020
- Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, H1 2020
- Prosthetic Joint infections - Dormant Projects, H1 2020
- Prosthetic Joint infections - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Prosthetic Joint infections, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Armata Pharmaceuticals Inc
- Arrevus Inc
- ContraFect Corp
- Lumobiotics GmbH
- Peptilogics Inc
- Sonoran Biosciences Inc
- Telephus Medical LLC
- TenNor Therapeutics Ltd
